Taysha Gene Therapies (NASDAQ:TSHA) Upgraded to Hold at Wall Street Zen

Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. The Goldman Sachs Group lifted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Wolfe Research assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.75.

Taysha Gene Therapies Stock Down 2.6%

TSHA stock opened at $4.10 on Friday. Taysha Gene Therapies has a twelve month low of $3.45 and a twelve month high of $7.30. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.34 billion, a PE ratio of -9.53 and a beta of 1.36. The business has a 50 day moving average of $4.49 and a 200 day moving average of $5.28.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. On average, research analysts forecast that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently added to or reduced their stakes in TSHA. Wellington Management Group LLP boosted its stake in shares of Taysha Gene Therapies by 534.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after buying an additional 3,349,244 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Taysha Gene Therapies by 19.6% during the third quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company’s stock valued at $16,135,000 after acquiring an additional 542,361 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Taysha Gene Therapies by 19.4% in the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock valued at $13,318,000 after acquiring an additional 483,620 shares during the period. Rice Hall James & Associates LLC lifted its holdings in Taysha Gene Therapies by 53.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,944,671 shares of the company’s stock valued at $8,693,000 after acquiring an additional 674,026 shares during the period. Finally, Bank of America Corp DE boosted its position in Taysha Gene Therapies by 45.5% in the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company’s stock worth $7,496,000 after purchasing an additional 524,366 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.